Glia as a Therapeutic Target: Selective Suppression of Human Amyloid-β-Induced Upregulation of Brain Proinflammatory Cytokine Production Attenuates Neurodegeneration
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
A corollary of the neuroinflammation hypothesis is that selective suppression of neurotoxic products produced by excessive glial activation will result in neuroprotection. We report here that daily oral administration to mice of the brain-penetrant compound 4,6-diphenyl-3-(4-(pyrimidin-2-yl)piperazin-1-yl)pyridazine (MW01-5-188WH), a selective inhibitor of proinflammatory cytokine production by activated glia, suppressed the human amyloid-β (Aβ) 1-42-induced upregulation of interleukin-1β, tumor necrosis factor-α, and S100B in the hippocampus. Suppression of neuroinflammation was accompanied by restoration of hippocampal synaptic dysfunction markers synaptophysin and postsynaptic density-95 back toward control levels. Consistent with the neuropathophysiological improvements, MW01-5-188WH therapy attenuated deficits in Y maze behavior, a hippocampal-linked task. Oral MW01-5-188WH therapy begun 3 weeks after initiation of intracerebroventricular infusion of human Aβ decreased the numbers of activated astrocytes and microglia and the cytokine levels in the hippocampus without modifying amyloid plaque burden or altering peripheral tissue cytokine upregulation in response to an in vivo inflammatory challenge. The results provide a novel integrative chemical biology proof in support of the neuroinflammation hypothesis of disease progression, demonstrate that neurodegeneration can be attenuated independently of plaque modulation by targeting innate brain proinflammatory cytokine responses, and indicate the feasibility of developing efficacious, safe, and selective therapies for neurodegenerative disorders by targeting key glial activation pathways.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798
Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease.
Griffin, W. S., Stanley, L. C., Ling, C., White, L., MacLeod, V, Perrot, L. J., White, C. L., & Araoz, C. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.19.7611 · Cited by 1,777 · cited 1×
“…underappreciated role of excessive glial activation, or neuroinflammation, in the pathophysiology of these progressive neurodegenerative disorders (Griffin et al., 1989, 1998; Wright, 2002; Craft et al., 2005a,b,c; Miller, 2005; Tuppo and Arias, 2005; Weydt and Moller, 2005) and raised the…”
BackgroundThe role of inflammation in Alzheimer’s disease
Tuppo, E. E., & Arias, H. R. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.07.009 · Cited by 734 · cited 2×
“Clinical and preclinical studies revealed a previously underappreciated role of excessive glial activation, or neuroinflammation, in the pathophysiology of these progressive neurodegenerative disorders (Griffin et al., 1989, 1998; Wright, 2002; Craft et al., 2005a,b,c; Miller, 2005; Tuppo and Arias, 2005; Weydt and Mo…”
BackgroundCrystal, H., Dickson, D., Fuld, P., Masur, D., Scott, R., Mehler, M., Masdeu, J., Kawas, C., Aronson, M., & Wolfson, L. (1988) · Neurology · doi:10.1212/wnl.38.11.1682 · Cited by 586
Alzheimer neuropathologic alterations in aged cognitively normal subjects
Davis, D. G., Schmitt, F. A., Wekstein, D. R., & Markesbery, W. R. (1999) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199904000-00008 · Cited by 516 · cited 2×
“Our data are consistent with clinical findings that cognitively intact individuals can have considerable amyloid deposits and that relevant clinicopathological endpoints in the human disease do not correlate directly or solely with the pattern of amyloid plaque deposition (Crystal et al., 1988; Davis et al., 1999; Gui…”
BackgroundResultPhenolic anti-inflammatory antioxidant reversal of Aβ-induced cognitive deficits and neuropathology
Frautschy, S. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00300-1 · Cited by 514
Yan, Q., Zhang, J., Liu, H., Babu-Khan, S., Vassar, R., Biere, A. L., Citron, M., & Landreth, G. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-20-07504.2003 · Cited by 469
NSAID and Antioxidant Prevention of Alzheimer's Disease: Lessons from In Vitro and Animal Models
COLE, G. M., MORIHARA, T., LIM, G. P., YANG, F., BEGUM, A., & FRAUTSCHY, S. A. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1332.005 · Cited by 129
Neuroinflammation: a potential therapeutic target
Craft, J. M., Watterson, D. M., & Van Eldik, L. J. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.5.887 · Cited by 116
Self-citationCraft, J. M., Watterson, D. M., Hirsch, E., & Van Eldik, L. J. (2005) · Journal of Neuroinflammation · doi:10.1186/1742-2094-2-15 · Cited by 96
Self-citation
Cited by
Role of pro-inflammatory cytokines released from microglia in Alzheimer's disease.
(2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2015.03.49 · Cited by 1,288
Astrocyte–neuron metabolic relationships: for better and for worse
Allaman, I., Bélanger, M., & Magistretti, P. J. (2011) · Trends in Neurosciences · doi:10.1016/j.tins.2010.12.001 · Cited by 639
Microglia, neuroinflammation, and beta-amyloid protein in Alzheimer’s disease
Cai, Z., Hussain, M. D., & Yan, L.-J. (2014) · International Journal of Neuroscience · doi:10.3109/00207454.2013.833510 · Cited by 583
The role of astroglia in neuroprotection
Bélanger, M., & Magistretti, P. J. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.3/mbelanger · Cited by 396
Jimenez, S., Baglietto-Vargas, D., Caballero, C., Moreno-Gonzalez, I., Torres, M., Sanchez-Varo, R., Ruano, D., Vizuete, M., Gutierrez, A., & Vitorica, J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3024-08.2008 · Cited by 383
“Activated inflammatory cells could mediate neuronal damage by producing toxic products, such as inflammatory cytokines, excitatory amino acids, reactive oxygen intermediates and other factors (Mrak and Griffin, 2005; Craft et al., 2006; Ralay Ranaivo et al., 2006; Zipp and Aktas, 2006).”
BackgroundTargeting p38 MAPK pathway for the treatment of Alzheimer's disease
Munoz, L., & Ammit, A. J. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.11.010 · Cited by 369
Chen, P.-S., Peng, G.-S., Li, G., Yang, S., Wu, X., Wang, C.-C., Wilson, B., Lu, R.-B., Gean, P.-W., Chuang, D.-M., et al. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001893 · Cited by 351
Fang, F., Lue, L.-F., Yan, S., Xu, H., Luddy, J. S., Chen, D., Walker, D. G., Stern, D. M., Yan, S., Schmidt, A. M., et al. (2010) · The FASEB Journal · doi:10.1096/fj.09-139634 · Cited by 335
Going the Extra (Synaptic) Mile: Excitotoxicity as the Road Toward Neurodegenerative Diseases
Armada-Moreira, A., Gomes, J. I., Pina, C. C., Savchak, O. K., Gonçalves-Ribeiro, J., Rei, N., Pinto, S., Morais, T. P., Martins, R. S., Ribeiro, F. F., et al. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00090 · Cited by 317
Esposito, G., Scuderi, C., Savani, C., Steardo, L., De Filippis, D., Cottone, P., Iuvone, T., Cuomo, V, & Steardo, L. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707337 · Cited by 308
“Although acute activation of glial cells may have important beneficial effects in the recovery of the CNS from a variety of insults, it is believed that a persistent activation amplifies inflammatory responses leading to a worsening of the consequences of injury (Ralay Ranaivo et al., 2006).”
Interleukin-1 and inflammatory neurodegeneration
Simi, A., Tsakiri, N., Wang, P., & Rothwell, N. J. (2007) · Biochemical Society Transactions · doi:10.1042/bst0351122 · Cited by 288
You, Z., Savitz, S. I., Yang, J., Degterev, A., Yuan, J., Cuny, G. D., Moskowitz, M. A., & Whalen, M. J. (2008) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2008.44 · Cited by 269
Microglia and neuroprotection: From in vitro studies to therapeutic applications
Polazzi, E., & Monti, B. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.06.009 · Cited by 262
Olah, M., Biber, K., Vinet, J., & W.G.M. Boddeke, H. (2011) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152711794488575 · Cited by 254
Microglia and mast cells: two tracks on the road to neuroinflammation
Skaper, S. D., Giusti, P., & Facci, L. (2012) · The FASEB Journal · doi:10.1096/fj.11-197194 · Cited by 235
Munoz, L., Ranaivo, H. R., Roy, S. M., Hu, W., Craft, J. M., McNamara, L. K., Chico, L. W., Van Eldik, L. J., & Watterson, D. M. (2007) · Journal of Neuroinflammation · doi:10.1186/1742-2094-4-21 · Cited by 224
“Screening for histological liver injury after chronic, therapeutic dose administration of compound was done as previously described [22,23].”
InfluentialSelf-citationInterleukin-1β impairs brain derived neurotrophic factor-induced signal transduction
Tong, L., Balazs, R., Soiampornkul, R., Thangnipon, W., & Cotman, C. W. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.02.027 · Cited by 222
Astrocytic dysfunction: Insights on the role in neurodegeneration
Rossi, D., & Volterra, A. (2009) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2009.07.012 · Cited by 219
Activation of the NLRP 3 inflammasome in microglia: the role of ceramide
Scheiblich, H., Schlütter, A., Golenbock, D. T., Latz, E., Martinez‐Martinez, P., & Heneka, M. T. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14225 · Cited by 147
Fernandez, A. M., Fernandez, S., Carrero, P., Garcia-Garcia, M., & Torres-Aleman, I. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.1002-07.2007 · Cited by 124
Tobinick, E. (2009) · CNS Drugs · doi:10.2165/11310810-000000000-00000 · Cited by 117
Ponce-Lopez, T. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094209 · Cited by 75
Howlett (2008) · PubMed · doi:10.14670/hh-23.67 · Cited by 65
Metadata
- Authors
- Ranaivo, H. R., Craft, J. M., Hu, W., Guo, L., Wing, L. K., Van Eldik, L. J., & Watterson, D. M.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2006-01-11
- Volume
- 26
- Issue
- 2
- Pages
- 662-670
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W1968286122
- Cited by
- 137
- References
- 12
- FWCI
- 9.70
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.